RxDoctor Payments Data

Eric Wasserman, MD

Ophthalmology · Stamford, CTNPI 1023016011

Payments from drug & device makers

$515in general payments, 2019–2025

Across 23 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$175
  • Tarsus Pharmaceuticals, Inc.$172
  • Aerie Pharmaceuticals, Inc.$50
  • AbbVie$47
  • Sun Pharmaceutical Industries Inc.$34
  • Alcon$20
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$515100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$515 in reported general payments places this provider in the 35th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$125,607
Medicare patients
415
Services billed
1,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine99$88,706
Cyclosporine16$8,893
Restasis MultidoseCyclosporine12$8,617
Timolol Maleate121$8,270
RocklatanNetarsudil Mesylat/Latanoprost15$7,696
TobradexTobramycin/Dexamethasone20$5,291
Brimonidine Tartrate33$4,388
CombiganBrimonidine Tartrate/Timolol11$3,591
Latanoprost254$3,268
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,175
Dorzolamide Hcl14$498
Azelastine Hcl20$486
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Combigan$47$100,914122 claims
Aerie Pharmaceuticals, Inc.Rocklatan$50$7,69615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →